title: Outcomes of treatment with AZT of patients with AIDS and symptomatic HIV infection.
abstract: Although many experimental treatments are being evaluated for the treatment of acquired immunodeficiency syndrome (AIDS) and symptomatic HIV infection (ARC), only zidovudine (AZT) has been shown to prolong the lives of such patients. This article reviews the authors' experience with 101 patients with AIDS (73) or ARC (28) treated with AZT at a public hospital clinic in Los Angeles County. The patients were seen at least monthly for five to 87 weeks (means = 27.6) by nurse practitioners and physicians. Initiation of AZT therapy required a CDC-defined diagnosis of AIDS or an absolute CD4 lymphocyte cell count of 200/mm3 or less. The demographic distribution of the patient population was as follows: Caucasian, 59; Hispanic, 22; and black, 20. The mean age of the population was 37.4 years, and the predominant risk factor was homosexual contact (76 percent). Forty-one patients required modification of their AZT doses secondary to anemia, neutropenia, a combination of anemia and neutropenia, or for personal reasons. Thirty-four of the 41 patients (83 percent) never returned to full dose after reductions. The majority of these patients (81 percent) had AIDS and/or CD4 lymphocyte counts less than 150/mm3. Hematologic toxicity was common; 27 percent required blood transfusions. Of the 101 patients followed from five to 87 weeks, 87 percent were surviving after a mean of 45 weeks of AZT therapy. The article underscores the effectiveness of AZT in prolonging the lives of AIDS and ARC patients.
authors.affiliation: Department of Medicine/Immunology, Harbor-UCLA Medical Center, Torrance.
authors.forename: P H
authors.initials: PH
authors.lastname: Cox
authors.forename: M A
authors.initials: MA
authors.lastname: Martin
authors.forename: C M
authors.initials: CM
authors.lastname: Styer
authors.forename: G N
authors.initials: GN
authors.lastname: Beall
mesh_terms: D000386:AIDS-Related Complex / Q000188:drug therapy* / Q000401:mortality / Q000451:nursing; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000401:mortality / Q000451:nursing; D000328:Adult; D005260:Female; D006779:Hospitals, Public; D006784:Hospitals, Teaching; D006801:Humans; D015141:Los Angeles; D008297:Male; D008875:Middle Aged; D010044:Outpatient Clinics, Hospital; D010353:Patient Education as Topic; D012189:Retrospective Studies; D015996:Survival Rate; D015215:Zidovudine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D015215:Zidovudine